Journal
INFECTIOUS DISEASES
Volume 51, Issue 3, Pages 161-167Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/23744235.2018.1527470
Keywords
Double carbapenem; CRE; blood stream infection; Klebsiella; KPC
Categories
Ask authors/readers for more resources
Background: Carbapenem-resistant Enterobacteriaceae (CRE) constitute a threat, since they cause infections with high mortality rates. Historically, polymyxin-based therapies have been the regimens of choice for CRE bloodstream infection (BSI). Recent studies have shown improved outcomes with beta-lactam-based therapies, including double carbapenem regimens for CRE BSIs compared to polymyxin-based regimens. The purpose of this report was to review the data supporting double carbapenem therapy for CRE BSI and provide recommendations regarding their use. Methods: A systematic literature search through 31 January 2018 was performed. Results: Multiple in vitro studies have described synergistic activity with ertapenem-based double carbapenem regimens for KPC-producing Enterobacteriaceae. Additionally, efficacy has been observed with double carbapenem regimens in multiple case reports and case series. A prospective multi-centre observational study of double carbapenem therapies in patients with CRE BSIs showed lower mortality compared to standard therapy. Conclusions: Clinicians should consider double carbapenem therapy as an option for treating CRE infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available